Repligen to Acquire BioLife Solutions in \$1.5 Billion Deal, Expanding Cell Therapy Capabilities
Key Highlights
- Repligen Corporation (NASDAQ: RGEN) to acquire BioLife Solutions, Inc. (NASDAQ: BLFS) for approximately \$1.5 billion in a cash and stock transaction.
- BioLife stockholders will receive \$31.00 per share, consisting of \$11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share.
- Transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least \$0.05 in year one and \$0.25 in year two.
- Repligen expects significant cost and operational synergies: at least \$20 million in year one and \$30 million in year two.
- BioLife brings a high-margin, recurring revenue business with leading biopreservation media used in 18 approved cell therapies and the majority of US cell therapy trials.
- Preliminary Q2 2026 results: Repligen reports 12% total revenue growth (13% organic); BioLife reports 21% revenue growth year-over-year.
- The deal is subject to BioLife stockholder approval, regulatory approvals, and customary closing conditions; expected to close in Q4 2026.
Transaction Details and Strategic Rationale
Repligen Corporation, a leader in bioprocessing technologies, has entered into a definitive agreement to acquire BioLife Solutions, a leading provider of cell processing tools and services for the cell and gene therapy (CGT) market. The deal, unanimously approved by both boards, values BioLife at approximately \$1.5 billion, to be paid 64% in Repligen stock and 36% in cash.
The acquisition is a strategic move to fast-track Repligen’s leadership in the high-growth cell therapy sector. BioLife’s market-leading portfolio—anchored by its CryoStor® biopreservation media—is deeply embedded in the cell therapy workflow and supports 18 commercially approved therapies. The combined company is expected to benefit from expanded global reach and a broader solutions offering for cell therapy customers, alongside enhanced financial performance and value creation for shareholders.
According to Repligen’s CEO, Olivier Loeillot, “The acquisition of BioLife represents a natural next step in the evolution of our strategy and further strengthens our position as a leading provider of mission-critical technologies for biologics manufacturing. BioLife brings a highly differentiated portfolio of products including a market-leading biopreservation media platform and other cell processing tools.”
BioLife’s Chairman and CEO, Roderick de Greef, added, “Repligen shares our commitment to providing innovative, differentiated, and enabling tools that help customers bring important therapies to patients. Its global commercial reach, complementary technologies and proven operating capabilities make Repligen an ideal partner.”
Financial Impact and Synergies
- Accretive Acquisition: The transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least \$0.05 in year one and \$0.25 in year two.
- Cost Synergies: Repligen anticipates at least \$20 million in synergies in the first year, rising to \$30 million in year two, primarily from eliminating public-company costs, G&A efficiencies, and manufacturing/supply-chain optimization.
- Conservative Revenue Synergy Forecast: Financial expectations only assume modest revenue synergies, leaving room for potential upside.
- Strong Balance Sheet: The cash portion of the deal will be funded from Repligen’s cash on hand, with a pro forma balance of over \$300 million post-transaction, preserving flexibility for future M&A or investments.
Preliminary Q2 2026 Results
- Repligen: Preliminary second quarter revenue growth of approximately 12% reported and 13% organic over Q2 2025, with expectations for strong year-over-year margin expansion. Full results to be reported July 28, 2026.
- BioLife: Preliminary Q2 2026 revenue of \$28.5 million, up 21% from \$23.4 million in Q2 2025. Full results to be reported August 6, 2026. No earnings call planned due to pending acquisition.
Deal Terms
- BioLife stockholders to receive \$11.25 in cash and 0.1442 shares of Repligen stock per BioLife share, totaling \$31.00 per share. This represents a 24% premium over BioLife’s 90-day VWAP as of July 21, 2026.
- The deal must be approved by BioLife shareholders and meet regulatory and standard closing conditions. The companies expect to close the transaction in Q4 2026.
- Repligen and BioLife have engaged leading advisors: Perella Weinberg and Goldman Sachs for Repligen; Centerview Partners for BioLife. Legal counsel provided by Goodwin Procter and K&L Gates, respectively.
Implications for Shareholders
- Significant Premium: The \$31.00 per share consideration represents a notable premium over recent trading prices, which may positively impact BioLife’s stock price in the short term.
- Accretive Financials: Expected immediate and growing accretion to Repligen’s EPS could enhance shareholder value.
- Potential for Further Upside: The conservative estimate for revenue synergies means there is potential for even greater financial benefits if integration is successful.
- Industry Position: The combined company will be a leader in the fast-growing cell therapy market, with a recurring revenue base and global reach, both of which are attractive to investors focused on long-term growth and stability.
- Risks and Uncertainties: The deal is subject to several risks, including regulatory and shareholder approval, integration risks, and market uncertainties. Any failure to close or unexpected integration challenges could affect share values for both companies.
Special Note on Shareholder Action
BioLife stockholders will receive further details and a proxy statement in advance of the shareholder vote. Investors are strongly encouraged to read all future filings and proxy materials related to the transaction. No action is required at this time, but participation in the upcoming vote will be crucial.
Conference Calls and Additional Information
- Repligen will host a conference call and webcast on July 22, 2026, at 8:30 a.m. ET to discuss the acquisition.
- Further information, including the registration statement and proxy materials, will be available via the SEC, Repligen, and BioLife websites.
Non-GAAP Metrics
Repligen reports organic revenue growth (non-GAAP) of 13% vs. total reported revenue growth (GAAP) of 12% in Q2 2026. See company filings for further explanation of non-GAAP measures.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should review all official company filings and consult their financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Please refer to the companies’ filings with the SEC for a discussion of these risks.
